標(biāo)題: Titlebook: Leading Pharmaceutical Innovation; How to Win the Life Oliver Gassmann,Alexander Schuhmacher,Gerrit Reepm Book 2018Latest edition Springer [打印本頁(yè)] 作者: LH941 時(shí)間: 2025-3-21 18:14
書(shū)目名稱Leading Pharmaceutical Innovation影響因子(影響力)
作者: evince 時(shí)間: 2025-3-21 20:47 作者: 不要嚴(yán)酷 時(shí)間: 2025-3-22 00:40 作者: Host142 時(shí)間: 2025-3-22 08:39 作者: Demulcent 時(shí)間: 2025-3-22 12:14
Oliver Gassmann,Alexander Schuhmacher,Max von Zedtwitz,Gerrit Reepmeyerent of immune disease by conditioning procedures (Ader, 1981). About twenty years ago the British immunologist John Humphreys published a study with others showing that the local inflammation and swelling that follows injection of an extract of tubercle bacilli into the skin (the tuberculin reaction作者: Arb853 時(shí)間: 2025-3-22 14:59 作者: occult 時(shí)間: 2025-3-22 17:51 作者: dysphagia 時(shí)間: 2025-3-22 22:24
Oliver Gassmann,Alexander Schuhmacher,Max von Zedtwitz,Gerrit Reepmeyersol, but the prospect of surgery can be just as effective, as can admission to hospital, the prospect of a college or university examination, or the expectation of exhausting physical exercise. On the one hand the physiological response to stress, as after injury, is of greatest concern, while on th作者: 變色龍 時(shí)間: 2025-3-23 02:12 作者: 柱廊 時(shí)間: 2025-3-23 06:29
the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation..978-3-030-09782-0978-3-319-66833-8作者: 松軟 時(shí)間: 2025-3-23 12:30
The Pipeline Challenge: How to Organize Innovation, innovation scissors.” The nature of the pipeline permits increasingly sophisticated portfolio analysis of drugs in development, offering pharma companies managerial options in managing individual drug candidates based on accessible competencies, risks, and expected benefits.作者: tooth-decay 時(shí)間: 2025-3-23 15:36
The Open Innovation Challenge: How to Partner for Innovation,nge the traditional, established inhouse-only R&D paradigm. An outlook of the rise of corporate venture funds in the pharma industry illustrates how important the management and valuation of intellectual property is in the life science industry.作者: Cursory 時(shí)間: 2025-3-23 19:57
The Internationalization Challenge: Where to Access Innovation,ngle of foreign R&D investors and from the perspective of indigenous Chinese players. Given the significant cost pressures in mature markets, reverse innovation in healthcare has drawn considerable attention by local governments.作者: 阻塞 時(shí)間: 2025-3-23 22:13
Book 2018Latest edition edition was expanded to reflect the latest updates in open and collaborative innovation, the greater strategic importance of venture capital and early-stage investments, and the new range of emerging technologies now being put to use in pharmaceutical innovation..作者: 連系 時(shí)間: 2025-3-24 06:08 作者: 起皺紋 時(shí)間: 2025-3-24 07:23 作者: 入會(huì) 時(shí)間: 2025-3-24 11:08
Innovation: Key to Success in the Pharmaceutical Industry, pharma companies, the cost structures for pharma innovation, and the nature of the productivity gap. We describe the blockbuster imperative and the pervasive concerns about risk and safety in pharma R&D, and conclude with a brief outlook on the main themes to be discussed in the remainder of the book.作者: ACRID 時(shí)間: 2025-3-24 16:40 作者: LEVER 時(shí)間: 2025-3-24 22:26 作者: indenture 時(shí)間: 2025-3-25 01:13
The Make-or-Buy Challenge: How to In- and Outsource Innovation, are discussed in detail and illustrated with cases from industry. We conclude with an example of how a breakthrough innovation can best be commercialized by a small pharma company using those make-or-buy options.作者: liposuction 時(shí)間: 2025-3-25 03:43
Future Directions and Trends,novation and change. Each of these levels is discussed in detail, breaking out the most important drivers and challenges. We conclude with a brief review of the main competencies that pharma innovators must master to remain at the forefront of their industry.作者: CAPE 時(shí)間: 2025-3-25 10:03
978-3-030-09782-0Springer International Publishing AG, part of Springer Nature 2018作者: 引起 時(shí)間: 2025-3-25 12:02 作者: 打包 時(shí)間: 2025-3-25 19:42 作者: Decibel 時(shí)間: 2025-3-25 22:30 作者: 允許 時(shí)間: 2025-3-26 03:49 作者: bifurcate 時(shí)間: 2025-3-26 05:14 作者: Essential 時(shí)間: 2025-3-26 09:58 作者: 采納 時(shí)間: 2025-3-26 12:53
Oliver Gassmann,Alexander Schuhmacher,Max von Zedtwitz,Gerrit Reepmeyermodern theater. But we have not given a lot of thought to the ways in which the bodies of actors might exhibit their agonized pain for an audience. These plays repeatedly call on the actor’s skill at counterfeiting pain. Although the evidence of its physical damage can be apprehended through wounds,作者: occult 時(shí)間: 2025-3-26 16:49 作者: 厭惡 時(shí)間: 2025-3-27 00:46 作者: MUTED 時(shí)間: 2025-3-27 04:58 作者: Fortify 時(shí)間: 2025-3-27 09:02 作者: Insul島 時(shí)間: 2025-3-27 12:09
Innovation: Key to Success in the Pharmaceutical Industry,ustomer and regulatory bodies in the development of new medicines, and the vanishing of easy targets. An overview is given of established and emerging pharma companies, the cost structures for pharma innovation, and the nature of the productivity gap. We describe the blockbuster imperative and the p作者: Ethics 時(shí)間: 2025-3-27 14:01
The Industry Challenge: Who Would Want to Be in This Business?,ors. We employ Porter’s Five-Forces industry analysis to examine the power of suppliers and buyers, potential competitors, the threat of substitute products, and rivalry among established companies. Regulators are also discussed, as they constitute a key stakeholder in the industry. We present key c作者: Extricate 時(shí)間: 2025-3-27 20:23
The Science and Technology Challenge: How to Find New Drugs,ral new discovery and development technologies. The rise of the biotech industry is the most obvious one, but new approaches in target discovery, high-throughput screening, combinatorial chemistry, hit and lead generation, bioinformatics, big data, proteomics and pharmacogenetics are also radically 作者: Infirm 時(shí)間: 2025-3-28 01:39
The Pipeline Challenge: How to Organize Innovation, research and development phases are highly regulated and defined with precision—a prime example of a stage-gate process. Given the long duration of the development of a new drug, and the increasing R&D costs per drug on average, the industry faces unfavorable innovation economics also known as “the作者: 貝雷帽 時(shí)間: 2025-3-28 02:22 作者: Fluctuate 時(shí)間: 2025-3-28 10:05 作者: 我要威脅 時(shí)間: 2025-3-28 11:53
The Internationalization Challenge: Where to Access Innovation,ology and talent wherever it emerges. Apart from the established centers of innovation in the United States, Europe and Japan, India, China and Singapore are rising attractors for global life science R&D. China as a pharma market and host of pharma R&D is highlighted as a case study, both from the a作者: Pandemic 時(shí)間: 2025-3-28 15:36 作者: Dignant 時(shí)間: 2025-3-28 20:24 作者: 終止 時(shí)間: 2025-3-29 00:18
